Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children

University of British Columbia

Status and phase: Completed; Phase 4

Conditions: Influenza

Treatments: Biological: adjuvanted Arepanrix

Study type: Interventional

Funder types: Other

Identifiers

NCT01000831

H09-02749

Details and patient eligibility

About

The purpose of this study is to compare the safety and effectiveness (immune response) to one or two doses of adjuvanted H1N12009 influenza vaccine in young children. An adjuvant is an additive that can boost the immune response. The study will enroll 300 children (ages 6-35 months). Participants will receive 2 doses of adjuvanted H1N12009 vaccine 3 weeks apart. Study procedures include: medical history, blood samples and completing a memory aid. Participants will be involved in study related procedures for approximately 6 weeks.

Full description

The goal of this study is to determine if one or two doses of the H1N12009 influenza vaccine are needed in young children, a population group at high risk of influenza infection and subsequent hospitalization.

The objectives of this study are two-fold:

1. To compare the safety and immunogenicity of 1 and 2 doses of adjuvanted H1N12009 influenza vaccine in children 6-35 months of age.
2. To conduct the trial soon after the vaccines become available and share the observations with health officials and the public as soon as possible.

Enrollment: 167 patients

Sex: All

Ages: 6 to 35 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Written informed consent provided for the subject by a parent or legal guardian
• Children age 6-35 months

Exclusion criteria

• Allergies to eggs, thimerosal, gentamicin sulphate or latex
• Life-threatening reaction to previous Flu vaccine
• Bleeding disorder
• Pregnancy
• Receipt of blood or blood products in past 3 months
• Chronic illness that could interfere with trial participation
• Compromised immune system
• Previous lab-confirmed H1N12009 infection
• Receipt of H1N12009 vaccine
• Receipt of Seasonal Influenza vaccine since March 2009

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

167 participants in 1 patient group

Adjuvanted Arepanrix 2 doses

Active Comparator group

Description:

Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart

Treatment:

Biological: adjuvanted Arepanrix